Skip to main content

Table 3 Outcome parameter comparing patients with DOAC and VKA pretreatment

From: MRI characteristics in acute ischemic stroke patients with preceding direct oral anticoagulant therapy as compared to vitamin K antagonists

 

DOAC pretreatment (N = 75)

VKA pretreatment (N = 61)

P

Confirmed therapeutic DOAC (N = 35)

Confirmed therapeutic VKA (N = 45)

P

Clinical outcome

 NIHSS at 24 h

2 (1–4)

3 (0–7)

0.359

3 (1–5)

4 (0–8)

0.565

 sICH ECASS-II

1/75 (1.3%)

1/61 (1.6%)

0.735

0

1/45 (2.2%)

0.298

 Duration of hospital stay, days

4 (2–8)

4 (2–8)

0.345

4 (3–7)

4 (2–8)

0.359

 90d mRS

1.5 (1–3)

3 (1.5–4)

0.001

1 (1–2)

3 (2–6)

< 0.001

 90d recurrent stroke

2/75 (2.7%)

4/61 (6.6%)

0.255

0

3/45 (6.7%)

0.185

Imaging

 Diameter axis 1, initial DWI, mm

18 (11–36)

20 (7–36)

0.607

19 (12–33)

13 (6–26)

0.111

 Diameter axis 2, initial DWI, mm

10 (6–19)

9 (5–23)

0.780

12 (6–19)

7 (4–16)

0.127

 Diameter hypoperfusion axis 1, mm

80 (38–118), N = 40

49 (36–67), N = 37

0.039

83 (27–118), N = 16

49 (36–66), N = 13

0.079

 Diameter hypoperfusion axis 2, mm

34 (18–40), N = 40

34 (14–40), N = 37

0.494

34 (20–46), N = 16

33 (13–38), N = 13

0.318

 DWI/Perfusion Mismatch

  

0.443

  

0.714

  - None

39/66 (59.1%)

29/53 (54.7%)

 

17/28 (60.7%)

26/40 (65.0%)

 

  - Small

4/66 (6.1%)

8/53 (15.1%)

 

1/28 (3.6%)

3/40 (7.5%)

 

  - Medium

4/66 (6.1%)

3/53 (5.7%)

 

2/28 (7.1%)

1/40 (2.5%)

 

  - Large

19/66 (28.8%)

13/53 (24.5%)

 

8/28 (28.6%)

10/40 (25%)

 

 Diameter axis 1, final FLAIR

18 (12–38)

27 (8–50)

0.409

18 (13–23)

20 (6–52)

0.945

 Diameter axis 2, final FLAIR

10 (6–22)

14 (7–25)

0.397

10 (6–22)

11 (5–25)

0.908

 Occlusion, any

22/75 (29.3%)

23/61 (37.7%)

0.361

9/35 (25.7%)

14/45 (31.1%)

0.628

 Target occlusion for EVT

20/75 (26.7%)

17/61 (27.9%)

1.000

9/35 (25.7%)

9/45 (20.0%)

0.596

 Thrombus length

8 (6–20), N = 19

13 (7–24), N = 13

0.388

15 (6–21), N = 7

11 (4–30), N = 6

0.836

 Multiple Lesions

31/56 (55.4%)

24/49 (49.0%)

0.560

10/21 (47.6%)

20/41 (48.8%)

1.000

 ICH, Heidelberg at follow up

  

0.024

  

0.126

  - 1a

5/75 (6.7%)

3/61 (4.9%)

 

4/35 (11.4%)

3/45 (6.7%)

 

  - 1b

0

7/61 (11.5%)

 

0

5/45 (11.1%)

 

  - 2

0

1/61 (1.6%)

 

0

0

 

  - 3c

1/75 (1.3%)

0

 

1 (2.9%)

0

 
  1. DOAC Direct oral anticoagulant, VKA Vitamin K antagonist, NIHSS National Institute of Health Stroke Scale, sICH ECASS II symptomatic intracranial hemorrhage according to the European Co-operative Acute Stroke Study-II definition, mRS modified Rankin Scale, DWI Diffusion weighted imaging, FLAIR Fluid attenuated inversion recovery sequence, EVT Endovascular stroke treatment, ICH Intracranial hemorrhage
Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us